Readoutin 45d
Biocad — BCD-217
Phase 3 primary completion: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma.
- Date
- Jan 2027
- Type
- Readout
- Indication
- Melanoma Stage III
Readoutin 45d
Phase 3 primary completion: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.